SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ziopharm
ZIOP 0.866-0.9%Jan 26 3:00 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: PLegee1/26/2017 4:41:36 PM
1 Recommendation

Recommended By
The Ox

   of 14
 
From the recent (Jan '17) JPM Healthcare Conference in San Francisco, ZIOP has announced that a Cooperative Research and Development Agreement with the National Cancer Institute has been established specifically using ZIOP's Sleeping Beauty cykotine controlling `rheostat' system. Details of the trial endpoints and registration start have not yet been announced.

This is quite an acknowledgement of their technology, effective IL-12 and Sleeping Beauty have demonstrated some eye opening results; real potential hope for a breakthrough. In addition, the FDA granted Ziopharm an 'End-of-Phase 2' meeting of the Phase 1 Glioblastoma trial. Apparently, this is not a common event and since safety seems to have already been established by interim Phase I data, the FDA wants to define a Phase III trial to quicken the pace of the clinical discovery/review process. Apparently, there is no standard front line treatment for GBM and the results already achieved in Phase I were encouraging enough for the FDA to act. The FDA meeting is said to be `imminent' and that trial registration will begin in 2017. ZIOP has good ties with MD Anderson so the qualified registrants may be less timely than typical cancer trials.

Plenty of Phase III trials from all disease categories have failed in the past, so this is still a speculative long shot, but nonetheless, it is sure is encouraging and hopeful for the unfortunate patients waiting for a medical breakthrough. Two huge issues dogging price per share are the 1) abysmal sentiment of the biotech sector regarding pricing/reimbursement and 2) ZIOP's need for cash prior to 2018. The CRDA above will help take some pressure off of cash, but unfortunately, a partnership or secondary will be required in the not so distance future. ZIOP indicated it has cash for operations through 1st qtr of 2018.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News